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pain, the distress caused by the pain and the pain’s experience are affected by many 
factors and these factors should be considered during the multidisciplinary care. We 
supposed that in case of hospice patients the circumstances, the place of the care 
and family support are such significant factors. Our aim was to compare hospice 
patients cared by home-hospice service and hospice department regarding pain and 
functional capabilityin Hungary. Methods: A quantitative crossectional study was 
performed in 2011-2012 using an anonymous questionnaire. Our tool contained a 
visual analog scale (VAS) to measure the intensity of pain, Beck depression inventory 
SF and self-developed questions. SPSS.18.0. programme was used for data analysis, 
regression analysis, khi-square, Mann-Whitney and Kruskal-Wallis tests were used to 
find out the correlations. Finally 120 patients (n= 120) participated in our study from 
the Southern Transdanubian region of Hungary. Results: The total intensity of pain 
was 4,4 ± 2,2 at the hospice department and 2,4 ± 0,9 in case of home hospice patients. 
There was a significant difference between the two groups (p< 0,001). We found signifi-
cant correlation regarding the intensity of pain and severity of depression (p< 0,001). 
The presence of pain affected the functional capability, the decrease of the capability 
was connected with the increase of the pain. ConClusions: We concluded that the 
place of the care is a determinative factor in case of hospice patient care. Part of the 
patient centralized care we have to focus on the family support and one of our chal-
lenge should be to teach the family how to care their relatives. With the enhance of 
the family care it is possible to fill the health care system’s gaps in.
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objeCtives: The objectives of the study were to assess the quality of life (QOL) 
among patients with esophageal/cardiac precursor lesion or cancer at differ-
ent stages, and evaluate changes in QOL during follow-up after primary treat-
ment. Methods: We enrolled 220 patients with esophageal or cardiac lesion 
between September 2007 and January 2010. They were followed up with the 
EuroQol-5 dimension (EQ-5D) for QOL before primary treatment and at 1, 6 and 
12 months after primary treatment. We calculated QOL scores (in terms of EQ-5D 
scores) based on the five-item descriptive system of health states of the EQ-5D and 
the UK preference weighting system. Results: In total, 74 patients with precancer-
ous lesion, 88 with early stage cancer, and 58 with advanced cancer participated 
in our survey. Prior to clinical treatment, the average EQ-5D score of patients with 
advanced cancer was 0.81±0.17 (mean ± standard deviation), significantly lower 
than that of patients with early stage cancer (0.87±0.09) or precancerous lesion 
(0.90±0.05) (P< 0.01). For precursor lesion, the score declined in the first month 
(P< 0.001), and gradually increased to a higher level at 12 months than before treat-
ment (P= 0.023). It showed a similar trend for early cancer (P< 0.05), though it was 
not statistically recovered even at 12 months (0.85±0.15 versus 0.87±0.09, P= 0.226). 
Regarding advanced cancer, the score showed a consistent decline, reached the 
lowest at 6 month, and finally rebounded to a similar level compared to that before 
treatment (0.80±0.13 versus 0.81±0.17, P= 0.624). ConClusions: Our results indicate 
that patients with precursor lesion or early stage esophageal or cardiac cancer have 
better QOL than do those with advanced cancer. Early detection and treatment 
improve QOL in the long run, despite QOL compromise in the immediate time. 
Particular attention and extra care should be given in the early period of treatment 
for patients.
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objeCtives: To develop an algorithm mapping the Functional Assessment of 
Cancer Therapy – Breast (FACT-B), to the 5-level EuroQoL Group’s 5-dimension 
questionnaire (EQ-5D-5L) index. Methods: A baseline survey of 238 self-admin-
istered breast cancer patients in Singapore was conducted. Regression models using 
ordinary least square, Tobit and censored least absolute deviation were fitted to 
predict the EQ-5D-5L index based on the five subscale (physical, social/family, emo-
tional, functional well-beings, additional concerns for breast cancer) scores of the 
FACT-B. Data from a follow-up survey of these patients were used to validate the 
results. Results: A model that maps the physical, emotional, function well-being 
subscales and the breast cancer concerns of the FACT-B to the EQ-5D-5L index was 
derived. The social/family well-being subscale was not associated to the EQ-5D-5L 
index. Although theoretic assumptions may not hold, ordinary least square showed 
better goodness-of-fit measures than other regression methods. The mean predicted 
EQ-5D-5L index within each performance status level deviated from the observed 
mean. However, the magnitudes of the deviations were smaller than the minimally 
important difference in EQ-5D for cancer patients. ConClusions: The mapping 
algorithm converts the FACT-B to the EQ-5D-5L index, which is essential in health 
economic evaluation. This enables oncologists and clinical researchers to obtain 
a quantitative utility summary of a patient’s health status when only the FACT-B 
is assessed.
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objeCtives: Report of health-related quality of life (HRQOL) among cervical cancer 
patients in Indonesia is very rare. This study aimed to examine the HRQOL of cervi-
cal cancer patients in Indonesia using EQ-5D-3L. Methods: A cross-sectional sur-
cational institution of Nagyatád town by a self-edited questionnaire. Women with 
an address in the city of Nagyatád and each having a 9-14-year-old daughter were 
chosen for the study. 247 questionaire were distributed and 186 were returned for 
evaluation. The study was performed in 2012. Results: 84.4% of the women knew the 
meaning of the acronym of HPV. Women living in marriage or cohabitation (χ 2= 5,966, 
p= 0,015), and with income above average (χ 2= 5,643, p= 0,018) were significantly better 
informed on HPV than single mothers. Only 26.9% of the women knew the role of the 
virus played in lip and oral cavity cancer, and 38.7% of them described the possibility 
of the infection in men. As a conclusion, 17.2% of 186 women gave correct answers 
on HPV. Significantly increased awareness proved to be for 38- year -old or older 
women of higher level education, or in intellectual work (p< 0,05). ConClusions: 
Despite Nagyatád women provided greater awareness on HPV causing cervical cancer 
compared to data in the literature, their overall knowledge on HPV is modest. In the 
future, a wide range of information should be provided for them.
PCN31
uNderstaNdiNg the ratioNale for resPoNses to a time-trade-off 
assessmeNt aNd williNgNess-to-Pay iN luNg CaNCer iN thailaNd
Crawford B1, Permsuwan U2, Thongprasert S3, Sakulbumrungsil R4, Chaiyakunapruk N5, 
Leartsakulpanitch J6, Petcharapiruch S7
1Adelphi Values, Tokyo, Japan, 2Chiang Mai University, Chiang Mai, Thailand, 3Faculty of Medicine 
Maharaj Nakorn Chiang Mai Hospital, Meung, Thailand, 4Chulalongkorn University, Bangkok, 
Thailand, 5Monash University Malaysia, Selangor, Malaysia, 6Pfizer (Thailand) Limited, Bangkok, 
Thailand, 7Pfizer (Thailand) Ltd., Bangkok, Thailand
objeCtives: The use of cost-effectiveness and valuation of the inherent value 
of health care interventions has been growing in Asia. To understand the think-
ing of subjects responding to a time-trade-off and willingness-to-pay assess-
ment, subjects were asked to describe what they considered when making their 
evaluation. Understanding their rationale will provide insights into the values of 
respondents. Methods: Data were collected from 300 respondents (150 lung can-
cer patients; 150 general public). Subjects responded to hypothetical lung cancer 
health states, described by three levels of severity and two levels of side-effects, and 
provided their valuation of their utility through a visual analog scale and time-trade-
off and their WTP to improve from one health state to another. Results: Subjects 
provided a range of responses to their time-trade-off from hope (“Cancer is curable 
/ Treatment may be effective”) to concerns of family burden and self-preservation 
(“Prefer to live as long as possible”). The most common reasons presented was 
being “Prefer to die than living with cancer” (43% of states) and “Financial burden 
to others / Prefer to save money for others” (19.3%). Older subjects (50+ years old; 
53.3%) and females (48.7%) more frequently stated being “Prefer to die than living 
with cancer”. Rural respondents stated “Prefer to live as long as possible” more 
frequently than urban respondents (19.6% vs 12.9%). Patients based their payments 
on their expectations of recovering (70.7%) and to relieve symptoms (16.0%). The 
general public also based their payments on the relief of symptoms (32.0%) followed 
by the desire to live longer (18.0%). ConClusions: Our study found that subjects 
were able to provide valid estimates from the time-trade-off and willingness-to-
pay. These rationales provide insights into how responses are formulated within 
an Asian country. Additional research will need to be conducted to compare these 
results to other Asian and Western countries.
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objeCtives: Breast cancer is the most commonly diagnosed malignancy worldwide. 
Our study aims at exploring Hungarian women’s relationship to screening tests with 
their socio-demographic data, their knowledge on the risk factors responsible for the 
formation of breast tumors, and the practical application of self-examination of the 
breast. Methods: Quantitative, cross-sectional, descriptive study was conducted in 
2013. Non-random, accidental sample included persons aged between 23and 65 with-
out a history of breast cancer. 160 self-administered questionnaires were distributed, 
of which 120 proved to be evaluated. χ 2-test was performed besides 95% probability 
(p< 0.05). Data analysis was performed with SPSS 20.0 programs. Results: 69.6% 
of the respondents have not participated in breast screening during their lifetime. 
The average age of the first presentation in mammographic screening accounted for 
43.08±7.74 years. Among women participating in screening 22.5% of the them come 
to screening yearly, 38.8% of them visit screening every two years, 10% of them come 
in 3 years, and 12.5% of them turn up even less frequently. We found no significant 
differences between the socio-demographic characteristics and the participation in 
screening (p> 0.05) 64.3% of the interviewed women performed self-examination on 
the breasts, but only 15.7% of the respondents performed it correctly, 5 days after 
menstruation. Eight pictures supported by text explanation were shown to dem-
onstrate self-examination in the questionnaire.17.39% of the women could estab-
lish the correct sequence. One or two errors were made by 45.22%, three or four 
errors were made by 16.52% of the respondents and 20% gave completely wrong 
sequence. ConClusions: It should be important to raise awareness in the screening 
process, emphasize the potential benefits, limitations, and possible adverse effects 
for all women and in particular the risk they may have if they fail to participate. In 
the long term, it is inevitable to develop responsible health behavior.
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objeCtives: Many challanges are experienced in the care of cancer patients like how 
to reach the painless condition and how to improve the quality of life. The intensity of 
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Japanese Pharmaceuticals and Medical Devices Agency (PMDA) websites. Relevant 
drugs were defined as related to the treatment of neoplasms, according to the World 
Health Organisation International Classification of Diseases Version 2010. Results: 
The FDA approved a total of 55 cancer drugs between 2004 and 2013 compared to 
45 by the PMDA, of which 24 drugs were approved by both organisations. Although 
less than half of currently FDA-approved cancer drugs are approved by the PMDA, 
87.5% of drugs approved by the FDA between 2004 and 2007 have subsequently been 
approved by the PMDA with an average delay of 2.95 years. Of the total number of 
drugs for all indications, 21% of FDA-approved drugs and 16% of PMDA-approved 
drugs were indicated for oncology. Although the proportion of drugs focused on 
breast cancer, lymphoma and bone marrow disorders were similar between the 
two organisations; the FDA had a higher proportion of drugs indicated for leuke-
mias and prostate cancer, whilst the PMDA had a larger focus on colorectal cancer 
drugs. ConClusions: From the analysis presented here, there are clear differ-
ences between cancer drug approval in Japan and the USA with regards to time-to-
approval of new drugs, as well as the specific treatment areas for which new drugs 
have been submitted.
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objeCtives: To review prevalence and risk factors of trastuzumab’s cardiotoxic 
effects in breast cancer patients. Methods: Retrospective chart review of 20 cases 
recieved trastuzumab for breast cancer treatment at Phramongkutklao hospital dur-
ing 2010-2011. Results: Average age of patients in this study was 58.2 +/- 9.3 years 
old. The most common stage of breast cancer were stage III (11/20, 55%). Average 
cycle per patients was 21.3 +/- 10.1. There were 12 patients (60%) completed 1 year 
course of treatment, 7 patients still recieving the treatment and 1 patient had to 
discontinue treatment before completion. There were 13 patients (65%) had declin-
ing in percentage of left ventricular ejection fraction after trastuzumab treatment, 6 
(46%) patients had less than 10% declining of left ventricular ejection fraction, equal 
to number of patients with 11-20% declining of left ventricular ejection fraction (6 
out of 12, 50%). In this study, we found 1 patients who had to discontinue treatment 
due to over 20% declining of ejection fraction. Due to the small number of cases, 
we did not found any statistical significant for the risk factors associated with the 
declining in ejection fraction among patients recieved trastuzumab treatment in 
this study. ConClusions: Cardiotoxicy in term of declining in percentage of left 
ventricular ejection fraction was not uncommon among breast cancer treated with 
trastuzumab. Closely monitoring patients with schedule echocardiogram is war-
ranted for safety use of this drug.
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objeCtives: The Chinese oncology market is increasingly important to multina-
tional and local pharmaceutical companies. However, access to high-cost medicines 
is fragmented within China. This study explored current prescribing and reimburse-
ment of high-cost, targeted therapies and differences between Tier 1 and Tier 2/3 
cities. Methods: Some 76 oncologists from different tier cities were surveyed 
regarding their current and expected future prescribing for gastric cancer (GC) and 
hepatocellular carcinoma (HCC). In addition, payers who influence reimbursement 
at national and/or regional levels were interviewed. Results: Chemotherapy still 
dominates GC and HCC treatment in China, with limited use of high-cost targeted 
therapies; reimbursement is considered the greatest barrier to accessing targeted 
therapies. Almost 60% of HCC patients do not receive sorafenib due to cost/reim-
bursement-related reasons. Patient assistance programs and private insurance 
schemes, along with government initiatives such as negotiation for selective pro-
vincial formularies inclusion and “disastrous diseases” coverage will help break this 
barrier. Patient share of high-cost GC and HCC therapies is expected to double over 
the next three years. We also found disparity in access to cancer therapies between 
different tier cities. More patients in Tier 1 cities have urban resident basic medical 
insurance than in Tier 2/3 cities (34% versus 24%). In Tier 1 cities, relatively more 
patients receive targeted therapy (23% versus 16%), compared with Tier 2/3 cities. 
Another compounding factor is that the cost of these therapies is lower in Tier 1 cit-
ies than in most Tier 2/3 cities (trastuzumab costs $1800 per cycle in Shanghai versus 
$2500 in Shijiazhuang). ConClusions: There is huge opportunity for high-cost 
cancer therapies in China; however, uneven reimbursement between cities means 
local market access strategies are required to maximize patient share.
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objeCtives: Aim of the study was concerned with formulation and evaluation of 
mouth dissolving tablets. Fluconazole is a broad spectrum triazole derivative useful 
in treatment of oropharyngeal and esophageal candidiasis, but it is poorly water 
soluble drug, for that an attempt was made to form complex with β -Cyclodextrin 
to make it water soluble and then deliver via buccal mucosa. Methods: The tab-
lets were prepared by wet granulation method using permeation enhancer and 
solubilizing agent β -Cyclodextrin and other excipients using 32 factorial designs. 
The amount of drug in each tablet was 50 mg and average weight of each tablet 
was found to be 230 mg. The prepared tablets were evaluated and compared in 
vey was conducted in 87 cervical cancer patients admitted to Dr. Sardjito Hospital, 
a referral hospital in Yogyakarta Province-Indonesia, between June to December 
2013. Data on HRQOL was collected using EQ-5D-3L (Indonesian version). As no 
Indonesian-EQ-5D-3L value set exists, Malaysian value set was used to calculate 
utility among these patients. Results: About 14%, 51%, 31% and 5% of patients 
were in stage I to IV, respectively. The most frequently reported problems were pain/
discomfort (67.82%) and anxiety/depression (57.47%). The mean of EQ-5D VAS score 
was 75.83 (SD= 17.03). The mean utility value was 0.830 (SD= 0.182), 0.751 (SD= 0.188), 
0.704 (SD= 0.205), and 0.766 (SD= 0.131) for patients with stage I to IV, respectively. 
Based on the stage of cervical cancer, the proportion of patients reporting problems 
in each dimension tended to increase from stage I to stage IV while the EQ-5D VAS 
score tended to decrease from stage I to stage IV. The utility value also tended to 
decrease from stage I to stage III, however it rather increased for patients with stage 
IV. ConClusions: Cervical cancer significantly affects patient’s HRQOL. Effort 
should be made to improve the quality of life of cervical cancer patients especially 
in term of pain /discomfort and anxiety/depression reduction.
CaNCer – health Care use & Policy studies
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objeCtives: Personalized medicine along with successful delivery of novel diag-
nostics has potential to revolutionize the patient care. However, the major challenge 
includes reimbursement system, specifically in obtaining coverage, appropriate 
coding, and value-based payment for diagnostics. To determine the coverage poli-
cies, extent of the tests covered and evidence basis for the coverage decisions by 
U.S. payers for genomic tests in breast cancer. Methods: We reviewed the cover-
age policies for genomic tests in breast cancer, coverage extent, and evidence for 
coverage decisions. An online search of top US insurers was conducted in January 
2014 to identify the coverage policies for genomic tests. In addition to FDA approval, 
the coverage policy and assessments were also reviewed. Results: In this search 
of insurance companies, 22 coverage policies for genomic testing were identified. 
Coverage determinations were made for 5 unique tests for disease diagnosis, prog-
nosis and risk assessment in the 22 policies analyzed. For genomic tests in Breast 
Cancer, one of the 5 tests was approved by the FDA and covered by only one insurer 
that issued a coverage decision on it. Coverage policies specific to disease-related 
genomic tests varied across the insurance companies that were evaluated. The 
Oncotype Dx is covered by all insurers to assess breast cancer recurrence risk, 
but considered investigational. Only 2 diagnostic tests were covered by atleast one 
insurer, however one of the tests was reviewed and covered by all insurers. Humana 
covered two tests; Mammaprint and Oncotype DX. The Mammaprint test for breast 
cancer risk recurrence had discordant coverage policies among tests reviewed by 
more than one insurer. ConClusions: Although some insurers are willing to pro-
vide coverage based on limited evidence of clinical utility, insurance coverage for 
genomic testing is low and variable. This is likely due to few studies published 
that demonstrate clinical utility and availability of alternative screening methods.
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objeCtives: To explore the effects of genetic testing of patients with breast cancer by 
Oncotype DX for decision of further therapy and their prognosis. Methods: Health 
economy model, using Cost-Utility Analysis (CUA), complemented by Budget-Impact 
Analysis (BIA) on public health insurance coverage in Slovakia. Markov Model (life 
time horizon) for BC patient management was developed, comparing diagnosis by 
Oncotype DX and standard diagnostic methods. Outcomes observed were decreased 
by number of women with chemotherapy (CT) and increased by proportion of women 
with hormonal treatment alone (HT) and their Recurence Score (RS, observed from 
test) in horizon of 10 years. Payer perspective and direct health care costs only, asso-
ciated with breast cancer diagnoses patient management were considered in CUA 
and BIA for diagnosis subgroups. Discount rate of 5% was used for costs as well as 
outcomes. Sensitivity analysis for major complications was implemented. Results: 
CUA for Oncotype DX vs. standard care associated with decreased proportion of CT 
and increased proportion of HT with cost per QALY 12 889 € and cost per LY 11 019 € . 
Net costs (BIA) associated with Oncotype DX for cohort of patients 1 200 are 3.92 mil. 
€ . ConClusions: Oncotype DX is considered cost-effective in terms of diagnoses 
and followed treatment of breast cancer patients. Oncologists are able to differentiate 
between a low or intermediate RS and a high RS using standard prognostic criteria. 
Provision of the actual RS changed the treatment recommendations in nearly 40% of 
cases, suggesting that the RS may reduce chemotherapy use.
PCN39
the differeNCes BetweeN CaNCer drug aPProvals iN jaPaN aNd  
the usa
Anderson R1, Brooks-Rooney C2
1Costello Medical Consulting Ltd., Cambridge, UK, 2Costello Medical Singapore Pte Ltd., Singapore
objeCtives: Cancer is amongst the leading causes of death globally and was 
responsible for a total of 8.2 million deaths worldwide in 2012. The aim of this 
study was to investigate the similarities and differences between the approval of 
new molecular entities and biologics for the treatment of cancers in Japan and the 
USA. Methods: Drugs approved from 2004 to 2013 were identified through publi-
cally available reports on the USA Food and Drug Administration (FDA) and the 
